
Steering committee
The Medthority Prostate Cancer Nexus is led by our steering committee, which represents the diverse range of medical professions within the multidisciplinary team.
Neal Shore, MD, FACS
Neal Shore serves as the Medical Director for the Carolina Urologic Research Center, Myrtle Beach, South Carolina, USA. Shore is the Chair of both the Prostate Cancer Academy and the Bladder/Kidney Cancer Academy, and the co-chair of the annual American Urological Association (AUA) International Prostate Forum.
Disclosures: AbbVie, Alessa Therapeutics, Alkido Pharma, Amgen, Arquer Diagnostics, Asieris Pharmaceuticals, Astellas, AstraZeneca, Bayer, Boston Scientific, Bristol Myers Squibb, Clarity Pharma, Clovis Oncology, Cold Genesys, Dendreon, Exact Images, Exact Sciences, FerGene, Ferring, Foundation Medicine, GC Oncology, Genentech, GenesisCare, Guardant Health, ImmunityBio, Incyte, Invitae, Janssen, Lantheus, Lilly, Mdxhealth, Merck, Minomic, Myovant Sciences, Myriad, NGM Bio, Nonagen Bioscience, Novartis, Novartis (Advanced Accelerator Applications), Nymox Pharmaceutical Corporation, Pacific Edge, Pfizer, Photocure, PlatformQ, Profound Pharma, Promaxo, Propella Therapeutics, Protara Therapeutics, Sanofi, Sesen Bio, Speciality Networks, Telix, Tolmar, UroGen Pharma, Vaxiion Therapeutics, and Vessi Medical.
Karim Fizazi, MD, PhD
Karim Fizazi is a medical oncologist at Institut Gustave Roussy and full professor in oncology at the University of Paris Saclay in Villejuif, France. Fizazi is the president of the French Groupe d’Etude des Tumeurs Genito-Urinaires (GETUG) and head of the genitourinary oncology group at Gustave Roussy.
Disclosures: Amgen, Arvinas, Astellas, AstraZeneca, Bayer, Clovis, CureVac, Daiichi Sankyo, Janssen, MacroGenics, MSD, Novartis (Advanced Accelerator Applications), Orion, Pfizer, and Sanofi.
Ken Herrmann, MD, MBA
Ken Herrmann is Professor of Nuclear Medicine at the Universitätsklinikum Essen, Germany. Herrmann is Section Editor of The Journal of Nuclear Medicine and Imaging Editor of European Urology.
Disclosures: AdvanCell, Aktis Oncology, Amgen, AstraZeneca, Bain Capital, Bayer, Boston Scientific, Convergent Therapeutics, Curium Pharma, Debiopharm, EcoR1, Fusion, GE Healthcare, Immedica, Isotopen Technologien München, Janssen, Merck, MSD, Molecular Partners, Novartis (Advanced Accelerator Applications), NVision, Pfizer, Pentixapharm, POINT Biopharma, Radiopharm Theranostics, Rhine Pharma, Siemens Healthineers, SOFIE Biosciences, Telix, Theragnostics, and Y-mAbs Therapeutics.
Nicholas David James BSc, MBBS, PhD, FRCP, FRCR
Nick James is Professor of Prostate and Bladder Cancer Research at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, UK. James is also a National Institute for Health and Care Research (NIHR) Senior Investigator and Deputy Dean of The Institute of Cancer Research. James’ research is focused on advanced prostate cancer and on bladder preservation in locally advanced disease.
Disclosures: Astellas, AstraZeneca, Bayer, Clovis, Gilead, Janssen, Merck, MSD, Novartis, and Sanofi.
Developed by EPG Health. This content has been developed independently of the sponsor, Pfizer, which has had no editorial input into the content. EPG Health received funding from the sponsor to help provide healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content. This content is intended for healthcare professionals only.
of interest
are looking at
saved
next event